Overview

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS)

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The safety and efficacy of AK1320 MS will be evaluated in patients with degenerative spondylolisthesis and concomitant symptomatic spinal stenosis who are undergoing decompression and single level instrumented posterolateral lumber autograft fusion surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Asahi Kasei Pharma Corporation
Collaborators:
Emergent Clinical Consulting
Emergent Clinical Consulting, LLC